Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 728983, 8 pages
Research Article

New Acetylcholinesterase Inhibitors for Alzheimer's Disease

1The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 10515 W Santa Fe Dr, Sun City, AZ 85351, USA
2Department of Pharmacology and Therapeutics, United Arab Emirates University, Al Ain, UAE

Received 31 July 2011; Revised 6 November 2011; Accepted 7 November 2011

Academic Editor: Anton P. Porsteinsson

Copyright © 2012 Mona Mehta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.